Rates of multidrug-resistant organisms (MDRO) colonization among intestinal transplant (ITx) recipients have not been reported. Colonization rates with vancomycin-resistant Enterococcus (VRE), carbapenem-resistant Gramnegative bacteria (CR-GNB), and methicillin-resistant Staphylococcus aureus (MRSA) were obtained retrospectively in adults undergoing ITx (isolated or multivisceral) from 1/2009 to 12/2015. We assessed for VRE, CR-GNB, and MRSA bacteremia during the first year post-transplant for patients colonized with VRE, CR-GNB, and MRSA, respectively, and for those who were not colonized. We evaluated whether the number of hospitalization days and one year post-transplant survival were different in MDRO-colonized patients. Forty-five ITx recipients were identified. Twenty-eight (62%) were colonized with MDRO [VRE in 22 (50%) patients, MRSA in seven (16%), and CR-GNB in six (15%)]. VRE and CR-GNB-colonized patients were more likely to develop VRE and CR-GNB bacteremia, respectively, than noncolonized patients [8/22 (36%) vs. 1/23 (4%), and 4/6 (67%) vs. 2/39 (5%), P < 0.05 for both]. There was no difference in one-year survival between MDROcolonized and noncolonized patients. However, survival was lower among MDRO-colonized patients who developed VRE, CR-GNB, or MRSA bacteremia (P < 0.001). MDRO colonization was common among our ITx recipients. VRE and CR-GNB bacteremia was more common among colonized patients, and survival was lower among MDRO-colonized patients who developed bacteremia. Transplant International 2017; 30: 924-931 
Introduction
Intestinal transplantation (ITx) is an acceptable therapeutic modality for irreversible intestinal failure. However, it is performed by very few transplant centers. Of a total of 653,111 solid organ transplants (SOT) performed in United States between 1998 and 2015, only 2,658 (0.4%) were ITx [1] .
Infections are very common after ITx. Silva el al reported an incidence of 2.81 episodes per 1000 transplant days in 87 ITx recipients. Of the nonopportunistic infections, 121 (60%) were bacterial (57%: Gram-negative, 31%: Gram-positive, and 12%: others). Bloodstream infection was seen in 72 (34%) of the cases [2] .
Infections due to multidrug-resistant organisms (MDRO) have become very common and are considered a substantial threat to the public health worldwide [3] . These infections are difficult to treat due to the paucity of effective antimicrobials, as well as the toxicity and cost of second-line agents that treat some of these infections [3] . SOT recipients colonized with MDRO are at a higher risk for developing an infection with the same organisms that they are colonized with, as it was demonstrated in a meta-analysis that showed that patients colonized with methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) were 5.5 times and 6.7 times more likely to develop MRSA and VRE infections, respectively, postliver transplant, respectively [4] . Twenty-two (39%) SOT recipients who had carbapenem-resistant Gram-negative bacteria (CR-GNB) colonization or infection prior to transplant developed CR-GNB infection post-transplant [5] . In another study, 20 (49%) of CR-Klebsiella pneumoniae-colonized liver transplant recipients developed Klebsiella pneumoniae infection (bloodstream infection in 18 and pneumonia in two patients) [6] .
The MDRO colonization data in patients undergoing ITx is scarce. In this study, we evaluated colonization rates and clinical outcomes among ITx recipients.
Patients and methods

Study population
This is a single-center retrospective study that was conducted at Jackson Memorial-Miami Transplant Institute, a 1558-licensed bed tertiary care teaching hospital in Miami, Florida. Our study was approved by the Institutional Review Board of University of Miami. The objectives of this study were to evaluate the MDRO colonization rates among ITx recipients and to determine whether MDRO colonization had an impact on clinical outcomes. All adult patients who underwent ITx (isolated and multivisceral) between 1/2009 and 12/2015 were evaluated. Typically, a multivisceral transplant includes stomach, pancreaticoduodenal region, small bowel, liver with or without the colon and spleen; the liver is spared in modified multivisceral transplants. The perioperative prophylactic antibiotic protocol at our institution during the study period included cefepime 2 g IV every 12 h, metronidazole 500 mg IV every 8 h and vancomycin 10 mg/Kg IV every 12 h for three days. Levofloxacin 500 mg IV every 24 h was recommended instead of cefepime for patients with documented penicillin allergy. The immunosuppressive protocol included antithymocte globulin 3 mg/Kg on days 0 and 2, rituximab 375 mg/m 2 on day 1, methylprednisolone 500 mg IV on days 0, 1, and 2, and 20 mg IV on day 3. On 3/2013, the protocol was changed to antithymocte globulin 2 mg/Kg on days 0, 2, 4, and 8 and rituximab 150 mg/m 2 on day 1 for all ITx recipients. In addition, multivisceral transplant recipients received methylprednisolone 500 mg IV on day 0, 250 mg on days 1, 2, and 3, and modified multivisceral and isolated transplant recipients received methylprednisolone 500 mg IV on days 0, 1, 2, and 3, 250 mg IV on day 4, and basiliximab 40 mg IV every four weeks started on day 14 for three doses. A postoperative gut decontamination protocol was used for those patients who underwent ITx prior to 3/ 2013. It consisted in administering 15 ml of sterile water mixed with polymyxin B 125,000 IU, gentamicin 20 mg and amphotericin B 12.5 mg every 6 h until tolerating enteral or oral feeds.
MDRO colonization
Patients were considered colonized with MDRO if they had at least one positive surveillance culture for VRE, MRSA, or CR-GNB within six months from transplant. Our hospital protocol includes weekly surveillance in all the intensive care units (ICU) from the date of admission (which could precede the date of transplant). Rectal swabs were obtained to detect VRE colonization, nasal swabs to detect MRSA, and rectal and/or respiratory specimens (only for patients on mechanical ventilation) to detect CR-GNB colonization. The CR-GNB included were Enterobacteriaceae, Pseudomonas, and Acinetobacter species. Carbapenem resistance was determined by VITEK 2. From 2009 to 2010, modified Hodge test was used to confirm CR-GNB for those Enterobacteriaceae isolates with meropenem minimum inhibitory concentration (MIC) of 2-4 lg/ml. From 2011 on, modified Hodge test was no longer required as the MIC susceptibility breakpoints were lowered. The susceptibility breakpoints for meropenem MIC were lowered from <4 lg/ml to < 2 lg/ml in 2012 for P. aeruginosa and in 2014 for Acinetobacter spp. No molecular testing was used to detect VRE, CR-GNB, or MRSA during the study period. We evaluated whether there were any differences in the number of patients screened and number of specimens collected per patient to detect VRE, MRSA, and CR-GNB colonization. In addition, we determined the onset of colonization after ITx for those who initially had negative surveillance cultures. No outbreaks were detected for any of the pathogens of interest during the study period.
General characteristics
We assessed whether there were any differences in demographics (gender and age), underlying intestinal disease, type of ITx, antibiotic exposure, and hospitalizations within three months prior to transplant, and length of primary hospitalization and ICU stay after transplantation between patients colonized with MDRO and those who were not colonized.
Clinical outcomes during the first year post-transplant
We evaluated for VRE, CR-GNB, and MRSA bacteremia during the first year post-transplant for those patients colonized with VRE, CR-GNB, and MRSA, respectively, and for those who were not. In addition, we determined the rates of acute cellular rejection (grade II or grade III) and graft-versus-host disease (GVHD), and number of hospitalizations days and hospital readmissions within a year after transplant, and one year post-transplant survival between patients colonized with MDRO and those who were not colonized. The presence of central venous catheters was investigated for those who developed bacteremia. The location of the patients at the onset of bacteremia and bacteremia sources were also evaluated. It was considered community onset if admitted ≤ 48 h from blood cultures collection. The cases of rejection and GVHD were identified by reviewing all the biopsies results. The histological criteria for the identification of acute cellular rejection used in our Institution came from the results of the pathology workshop at the VIII International Small Bowel Transplant Symposium [7] .
Statistical analyses
Chi-square and Fisher's exact tests were used as appropriate to assess bivariate associations between categorical variables; Student's t-test or Mann-Whitney test were used to compare continuous variables between groups, depending on normality of the distributions. A P-value <0.05 was considered significant.
Results
MDRO colonization
Number of patients screened and specimens obtained, and colonization rates A total of 45 consecutive adult ITx patients were evaluated (Table 1 ). There were no differences in the number Twenty-eight (62%) patients were colonized with MDRO [VRE in 22 (50%), MRSA in 7(16%), and CR-GNB in six (15%) patients]. Seven (16%) were colonized with more than one organism (VRE/CR-GNB and VRE/MRSA in three patients each and CR-GNB/MRSA in one). The species of the Enterococcus colonizers were not reported as part of our hospital protocol. The CR-GNB colonizers were Pseudomonas aeruginosa (three patients), Klebsiella pneumoniae (two patients), and Acinetobacter baumannii (one patient). P. aeruginosa was detected by respiratory culture in one patient and by rectal culture in the other two patients (no respiratory culture obtained in one of them). K. pneumoniae was detected by rectal and respiratory culture in one patient and by rectal culture in the other (no respiratory culture obtained), and A. baumannii was detected by rectal and respiratory cultures.
Timing of MDRO colonization with respect to ITx
Eight (36%) and five (71%) of the patients that screened positive for VRE and MRSA were already colonized by the time of transplant. In contrast, none of those who screened positive for CR-GNB were colonized at the time of ITx. Post-transplant colonization with VRE, CR-GNB, and MRSA, occurred in 14 (64%), six (100%), and two (29%) patients, respectively. Among those patients with post-transplant colonization, the median time from ITx to first positive surveillance culture for VRE, CR-GNB, and MRSA was 73.5 (range: 12-177), 56.5 (24-131), and 95.5 (62-129) days, respectively.
General characteristics
There were no differences in gender, age, underlying intestinal disorders and type of ITx between patients who were colonized with MDRO and those who were not (Table 1 ). There were no differences in antibiotic exposure within three months prior to ITx between MDRO-colonized and noncolonized patients. However, colonized patients were more likely to have been hospitalized within three months prior to transplant [22 (79%) vs. 8 (47%), P = 0.03] ( Table 1 ). There were no differences in length of primary hospitalization and ICU stay after transplantation between both groups (Table 1) . Five colonized and six noncolonized patients died during their primary hospitalization after transplantation. They died at days 2, 10, 58, 82, and 187, and 1 (three patients), 75, 79, and 130, respectively. Note that three patients in the noncolonization group were not included in the ICU stay analysis as they were not admitted to the ICU (they died in the operative room).
Clinical outcomes during the first year post-transplant VRE, CR-GNB, and MRSA bacteremia VRE and CR-GNB bacteremia were more frequent among those patients colonized with VRE and CR-GNB, respectively, compared to those who were not [VRE: 8/22 (36%) vs. non-VRE: 1/23 (4%), P = 0.009, and CR-GNB: 4/6 (67%) vs. non-CR-GNB: 2/39 (5%), P = 0.001]. All the cases of VRE bacteremia were due to E. faecium (Table 2) . CR-GNB bacteremia in the CR-GNB-colonized patients was only due to the bacteria they were colonized with except for the patient colonized with A. baumannii who had A. baumannii and A. iwoffii bacteremia ( Table 2 ). The ICU was the most common location at the onset of bacteremia, all patients but one had central venous catheters at the time of bacteremia, and the source of bacteremia was unclear in seven of the cases, due to central lineassociated bloodstream infection (CLABSI) in four, bowel ischemia in two and due to peritonitis, urinary tract infection and septic arthritis in one case each ( Table 2 ). The median time from colonization to VRE and CR-GNB bacteremia were 61 days (range: 4-101) and 64.5 days (36-93), respectively. The rates of VRE and CR-GNB bacteremia were not different between patients who received postoperative gut decontamination and the older immunosuppressive protocol and those who received the newer immunosuppressive protocol [5/14 (36%) vs. 4/31 (13%), P = 0.11 and 3/14 (21%) vs. 3/31 (10%), P = 0.36], respectively.
Acute cellular rejection and GVHD
There was no difference in acute cellular rejection (grade II or III) between patients colonized with MDRO and those who were not [8 (29%) vs. 2 (12%), P = 0.28]. Three patients had grade II and five patients had grade III rejection among the MDRO-colonized patients, and one patient had grade II and one had grade III rejection among the noncolonized patients. There was no difference either in the rates of GVHD between MDRO-colonized and not colonized patients [6 (21%) vs. 4 (24%), P > 0.99].
Number of hospitalization days and hospital readmissions within a year post-transplant and one year post-transplant survival There was a trend toward more hospitalizations days within a year after ITx among those who were colonized with MDRO compared to those who were not (122.9 AE 68.2 vs. 79.6 AE 72.4 days, P = 0.05). MDROcolonized patients were more likely to be readmitted during the first year post-transplant compared to those who were not. However, it did not reach statistical significance (4.6 AE 3.1 vs. 3.2 AE 2, P = 0.18). Please note that the five colonized and six noncolonized patients who died during the primary hospitalization were not included in this analysis. There was no difference in one-year survival between patients colonized with MDRO and those who were not [16 (57%) vs. 11 (65%), P = 0.62]. However, survival was lower among MDRO-colonized patients who developed bacteremia due to VRE, CR-GNB, or MRSA compared to colonized patients who did not, [2/11(18%) vs. 15/17(88%), P < 0.001].
Discussion
To the best of our knowledge, this is the first study to report rates of colonization with MDRO in ITx recipients. It is concerning that more than 60% of our screened patients were colonized with either VRE, MRSA, or CR-GNB. VRE was the most commonly isolated organism, colonizing half of our patients. In addition, the rates of MDRO colonization found in this population may be an underestimate as outpatients or hospitalized patients outside of the intensive care units were not screened (all ITx recipients are immediately hospitalized in the surgical intensive care unit posttransplant for three days or longer as needed). For the purpose of this study, we only included VRE, MRSA, and CR-GNB as MDRO. We did not consider other MDRO such as extended-spectrum beta-lactamases (ESBL)-producing organisms as our infection control program does not screen for those. In our institution (inpatient setting, including intensive care units), 77% of the E. faecium isolates in 2010 and 69% in 2014 were VRE, 53% of the S. aureus isolates in 2010 and 48% in 2014 were MRSA, and 1% and 3% of the K. pneumoniae, 14% and 15% of the P. aeruginosa, and 52% and 40% of the A. baumannii isolates were carbapenemresistant in 2010 and 2014, respectively [data not published].
Consistent with prior reports in nontransplant patients [6] , our study showed that recent hospitalization is a risk factor for MDRO colonization. Recent antibiotic exposure is another known risk factor [8] [9] [10] . However, it was not demonstrated in our study likely due to its small size.
We observed that VRE and CR-GNB-colonized patients were more likely to develop VRE and CR-GNB bacteremia, respectively, compared to patients who were not colonized with these bacteria. These findings are consistent with previous reports [4] [5] [6] . VRE colonization leading to infection is less frequent in kidney transplant recipients [11] . The source of bacteremia was unclear in seven (44%) of the cases. Gut translocation could have been a possible source in some of them. Four of the cases were due to CLABSI meeting the National Healthcare Safety Network definition [12] . Our hospital policy in CLABSI prevention during the study period consisted in hand hygiene by washing hands for a minimum of 15 seconds or using an Table 2 . Bacteremia due to VRE, CR-GNB, and MRSA in colonized and noncolonized patients §DAP susceptible not checked. ¶Not screened for CR-GNB during the preceding two months. **CST susceptibility not checked. † †Rectal screening negative five days prior bacteremia.
alcohol-based waterless hand cleaner and rubbing hands until dry, maximal barrier precautions by having the operator and assistants wearing cap, mask, sterile gown, and gloves and the patient covered from head to toe with a sterile drape, with a small opening for the site of insertion, optimal catheter site selection (the subclavian line site was preferred for nontunneled catheters), skin antisepsis with 2% chlorhexidine, and daily review of line necessity. In addition, all personnel who inserted/ observed insertion of a central venous catheter were required to complete an online educational module. Infections with MDRO are associated with poor outcomes in SOT recipients. Liver transplant candidates and recipients with VRE infections have an increased risk of death [13] . S. aureus infections were associated with a significant shorter survival in a study including small bowel and multivisceral transplant recipients [14] . 18% of SOT (mostly liver or intestinal) recipients with CR-Klebsiella pneumoniae bacteremia died of septic shock [15] . Our study showed lower one year posttransplant survival among those MDRO-colonized patients who developed bacteremia.
This study has limitations. Our data was generated in a relatively small cohort which could have prevented from achieving statistically significance in some of the analyses. Larger studies are also needed to analyze isolated and multivisceral transplant recipients separately as their mortality rates and risk for infection may be different. We did not collect infection data other than bacteremia so we probably underestimated the risk of infection following colonization. Prospective studies evaluating at all types of infections are needed. We reported the data from a single institution so our results may not apply to other institutions which may have different rates of MDRO, surgical techniques, immunosuppression and antimicrobial prophylaxis protocols. Despite these limitations, our observations provide novel insights into the rates of MDRO colonization and associated clinical outcomes among ITx recipients at one of the largest transplant centers performing ITx in the US.
In conclusion, MDRO, especially VRE, colonization was common among our ITx patients. VRE and CR-GNR bacteremia was more common among VRE and CR-GNB-colonized patients, respectively, and 1-year survival was lower among MDRO-colonized patients who developed bacteremia.
